摘要
目的探讨依达拉奉治疗老年短暂性脑缺血（TIA）患者的效果及对血液流变学的影响。方法选取2012年1月至2014年11月我院收治的80例老年TIA患者作为研究对象,按数字表法随机分为对照组和观察组,每组各40例;2组患者均给予常规治疗,观察组患者加用依达拉奉注射液静脉滴注30 mg/次,2次/d,2组均连续治疗2周,观察2组治疗后临床疗效及血液流变学变化并记录不良反应;比较2组治疗前后C反应蛋白（CRP）、基质金属蛋白酶-9（MMP-9）及促红细胞生成素（EPO）水平变化。结果治疗后观察组总有效率为90.00%,显著高于对照组72.50%,差异具有统计学意义（χ^2=4.021,P〈0.05）;治疗后2组全血高切黏度、全血低切黏度、血浆黏度、纤维蛋白原水平均比治疗前显著降低（P〈0.05）;治疗后,观察组全血高切黏度、全血低切黏度、血浆黏度、纤维蛋白原水平明显低于对照组,差异具有统计学意义（P〈0.05）;2组CRP、MMP-9水平比治疗前显著降低（P〈0.05）,EPO水平比治疗前显著升高（P〈0.05）;治疗后,观察组CRP、MMP-9及EPO水平与对照组比较,差异均具有统计学意义（P〈0.05）。结论依达拉奉对于老年TIA疗效显著,可有效改善患者血流动力学,通过促进EPO水平,降低CRP、MMP-9水平发挥神经保护作用。
Objective To investigate the efficacy of edaravone in elderly patients with transient ischemia（ TIA） and its influence on blood rheology. Methods A total of 80 elderly patients with TIA from January 2012 to November 2014 in our hospital were selected and randomly divided into control group and observation group according to number table,with 40 cases in each group. Patients were given conventional treatment,while patients in the observation group were added with edaravone intravenous injection 30 mg / times,2 times / d. Adverse reactions,clinical efficacy and its influence on blood rheology were recorded after two weeks＇ treatment. The levels of CRP,MMP-9 and EPO were detected and compared before and after treatment. Results After treatment,the total effective rate in observation group was 90. 00%,which was significantly higher than that in control group（ 72. 50%）（ χ~2= 4. 021,P 0. 05）. The levels of high shear whole blood viscosity,low shear whole blood viscosity,plasma viscosity,fibrinogen were significantly decreased in two groups after treatment（ P0. 05）,and there was significant difference between two groups（ P0. 05）. The levels of CRP,MMP-9 were significantly decreased and the level of EPO was significantly increased in two groups after treatment（ P0. 05）,and there was significant difference between two groups（ P0. 05）. Conclusions Edaravone in treatment of TIA in elderly patients can effectively improve hemodynamics. It has the neuroprotective effect by promoting EPO level and reducing CRP,MMP-9levels.
出处
《实用老年医学》
CAS
2016年第4期326-328,共3页
Practical Geriatrics
基金
国家自然科学基金资助项目(81000504)
